key: cord-0693186-ly2hzqm2
authors: Adachi, Shunichi; Sonoda, Motoshi; Ishimura, Masataka; Eguchi, Katsuhide; Tanaka, Tamami; Motomura, Yoshitomo; Ohga, Shouichi
title: Optimal biologics for juvenile idiopathic arthritis in an infection with SARS‐CoV‐2 α‐variant
date: 2021-11-06
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13686
sha: 9a89edda0f52caa26f644e9daff8137d0b5ef909
doc_id: 693186
cord_uid: ly2hzqm2

nan

To the Editor,

The worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still raging and continues to have a serious impact on global health care and the economy across nations. The risk of severe COVID-19 is of concern for patients with rheumatic diseases (RMDs) using disease-modifying anti-rheumatic drugs (DMARDs) including biologics. 1 COVID-19 appears to show a milder clinical course in children than in adults, but multisystem inflammatory syndrome in children (MIS-C) occurs as a life-threatening complication due to unknown causes. 2 The emergence of newly The patient was a 7 years-old girl who was diagnosed as having systematic JIA at 2 years of age. She achieved remission without macrophage activation syndrome (MAS) for 5 years after the introduction of tocilizumab (8 mg/kg) every 4 weeks and methotrexate (MTX, 7 mg/m 2 ) weekly. She developed fever and cough three days after her father was diagnosed to have SARS-CoV-2 lineage B.1.1.7 according to a reverse transcription-polymerase chain reaction (RT-PCR) test.

The patient presented with a fever of up to 38.0°C for two days, and then, a positive RT-PCR result prompted the girl to be hospitalized at our institution for care and isolation. On admission, she was afebrile and free from respiratory symptoms or desaturation. Chest X-rays showed no abnormality. Laboratory tests were unremarkable as follows: leukocytes, 3.9 × 10 9 /L (reference range [rr], 3.3-8.6 × 10 9 /L); neutrophils, 1.7 × 10 9 /L (rr, 1.5-8.0 × 10 9 /L); lymphocytes, 1.6 × 10 9 /L (rr, 1.5-7.0 × 10 9 /L); hemoglobin, 13.3 g/dl (rr, 11.5-14.4 g/dl); platelet count, 22.3 × 10 9 /L (rr, 18-51 × 10 9 /L); C-reactive protein, 0.01 mg/dl (rr, <0.14 mg/dl); lactate dehydrogenase, 259 U/L (rr, 175-320 U/L); fibrinogen, 218 mg/dl (rr, 200-400 mg/dl); prothrombin time, 11.1 s (rr, 10.0-13.5 s); D-dimer, <0.5 mg/L (rr, <0.5 mg/L); ferritin, 24.1 ng/ml (rr, 6.2-138.0 ng/ml); and matrix metalloproteinase-3, <10 ng/ml (rr, <10 ng/ml). The serum cytokine levels at the diagnosis of COVID-19

showed slightly elevated levels of TNFα (26.4 pg/ml; rr, <10 pg/ml), IL-6 (64.1 pg/ml; rr, <10 pg/ml), and IL-8 (41.6 pg/ml; rr, <10 pg/ml). 

COVID-19, juvenile idiopathic arthritis, tocilizumab

This study was supported by JSPS KAKENHI (grant number JP 21K07847).

The authors have declared no conflicts of interest. 

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children

Clinical course of COVID-19 in children with rheumatic disease under biologic therapy

Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members

The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis

COVID-19 in children with rheumatic diseases in the spanish national cohort EPICO-AEP

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19

Seroprevalence of antibodies against SARS-CoV-2 in children with juvenile Idiopathic arthritis a case-control study

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: covizumab-6 observational cohort

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7